These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 38142587)

  • 41. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolving liver disease insights from NAFLD to MASLD.
    Fan X; Song Y; Zhao J
    Trends Endocrinol Metab; 2024 Aug; 35(8):683-686. PubMed ID: 38429162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
    De A; Bhagat N; Mehta M; Taneja S; Duseja A
    J Hepatol; 2024 Feb; 80(2):e61-e62. PubMed ID: 37558135
    [No Abstract]   [Full Text] [Related]  

  • 44. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Zhao S; Guo Y; Yin X
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
    Suzuki K; Tamaki N; Kurosaki M; Takahashi Y; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
    Hepatol Res; 2024 Jun; 54(6):600-605. PubMed ID: 38234088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum.
    Vidal-Cevallos P; Sorroza-Martínez AP; Chávez-Tapia NC; Uribe M; Montalvo-Javé EE; Nuño-Lámbarri N
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.
    Lu X; Yang R; Chen Y; Chen D
    iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alterations of the duodenal mucosal microbiome in patients with metabolic dysfunction-associated steatotic liver disease.
    Ren M; Pan H; Zhou X; Yu M; Ji F
    Sci Rep; 2024 Apr; 14(1):9124. PubMed ID: 38643212
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Usefulness of a questionnaire for assessing the relationship between eating behavior and steatotic liver disease among Japanese male young adults.
    Miwa T; Tajirika S; Hanai T; Imamura N; Adachi M; Horita R; Fukao T; Shimizu M; Yamamoto M
    Sci Rep; 2024 Jan; 14(1):2194. PubMed ID: 38273030
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis.
    Lee JH; Park J; Ahn SB
    Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Kanwal F; Neuschwander-Tetri BA; Loomba R; Rinella ME
    Hepatology; 2024 May; 79(5):1212-1219. PubMed ID: 38445559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges.
    Phoolchund AGS; Khakoo SI
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natural history and progression of metabolic dysfunction-associated steatotic liver disease.
    Hagström H; Shang Y; Hegmar H; Nasr P
    Lancet Gastroenterol Hepatol; 2024 Oct; 9(10):944-956. PubMed ID: 39243773
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-invasive testing and risk-stratification in patients with MASLD.
    Zoncapè M; Liguori A; Tsochatzis EA
    Eur J Intern Med; 2024 Apr; 122():11-19. PubMed ID: 38246813
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus.
    Chen L
    World J Hepatol; 2023 Dec; 15(12):1253-1257. PubMed ID: 38223415
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic Muddle. MASLD and MASH on the Horizon.
    Meagher T
    J Insur Med; 2023 Jul; 50(2):147-149. PubMed ID: 38358924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pathophysiology of MASLD: an immunometabolic perspective.
    Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
    Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BDE-47 induces metabolic dysfunction-associated steatotic liver disease (MASLD) through CD36-mediated increased fatty acid uptake and PPARα-induced abnormal fatty acid oxidation in BALB/c mice.
    Xia B; Yu R; Liu J; Liu D; Li S; Yang L; Liu N; Liang B; Zeng J; Wei J; Lin G
    Toxicol Lett; 2024 Jan; 391():100-110. PubMed ID: 38040069
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Electrocardiographic abnormalities in patients with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.
    Dimala CA; Nso N; Wasserlauf J; Njei B
    Curr Probl Cardiol; 2024 Jul; 49(7):102580. PubMed ID: 38653446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.